Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2604748rdf:typepubmed:Citationlld:pubmed
pubmed-article:2604748lifeskim:mentionsumls-concept:C0003392lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0025663lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0014442lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0025513lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2604748lifeskim:mentionsumls-concept:C0439831lld:lifeskim
pubmed-article:2604748pubmed:issue24lld:pubmed
pubmed-article:2604748pubmed:dateCreated1990-2-8lld:pubmed
pubmed-article:2604748pubmed:abstractTextMetabolic activation is a prerequisite for the antitumor activity of certain drugs such as cyclophosphamide. In vitro assays require systems for metabolic activation to reveal the toxicity of such compounds for tumor cells. Although a number of methods utilizing systems for the in vitro metabolic activation of drugs have been published, practical assays applicable to large scale screening for such agents have been lacking. We, therefore, now report that incorporation of a liver subcellular fraction (S9) into a recently established cell growth inhibition assay (microculture tetrazolium assay) significantly increased the cytotoxicity of cyclophosphamide. Under optimal conditions, the 50% growth inhibitory concentration was decreased in the presence of S9 from more than 600 micrograms/ml to less than 4 micrograms/ml, depending upon the cell line. The method also proved suitable for studies investigating metabolic detoxification (enzymatically or non-enzymatically) by conjugation reactions. For example, glutathione (5 mM) markedly reduced the cytotoxicity of activated cyclophosphamide. In contrast, the addition of UDP glucuronate (10 mM) in the presence of the UDP-glucuronosyltransferase activator UDP-N-acetylglucosamine (10 mM) had little effect on cyclophosphamide toxicity.lld:pubmed
pubmed-article:2604748pubmed:languageenglld:pubmed
pubmed-article:2604748pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2604748pubmed:citationSubsetIMlld:pubmed
pubmed-article:2604748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2604748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2604748pubmed:statusMEDLINElld:pubmed
pubmed-article:2604748pubmed:monthDeclld:pubmed
pubmed-article:2604748pubmed:issn0006-2952lld:pubmed
pubmed-article:2604748pubmed:authorpubmed-author:McMahonJ BJBlld:pubmed
pubmed-article:2604748pubmed:authorpubmed-author:ShoemakerR...lld:pubmed
pubmed-article:2604748pubmed:authorpubmed-author:SteinmannG...lld:pubmed
pubmed-article:2604748pubmed:authorpubmed-author:LebsanftJJlld:pubmed
pubmed-article:2604748pubmed:issnTypePrintlld:pubmed
pubmed-article:2604748pubmed:day15lld:pubmed
pubmed-article:2604748pubmed:volume38lld:pubmed
pubmed-article:2604748pubmed:ownerNLMlld:pubmed
pubmed-article:2604748pubmed:authorsCompleteYlld:pubmed
pubmed-article:2604748pubmed:pagination4477-83lld:pubmed
pubmed-article:2604748pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:meshHeadingpubmed-meshheading:2604748-...lld:pubmed
pubmed-article:2604748pubmed:year1989lld:pubmed
pubmed-article:2604748pubmed:articleTitleA rapid in vitro method for the evaluation of potential antitumor drugs requiring metabolic activation by hepatic S9 enzymes.lld:pubmed
pubmed-article:2604748pubmed:affiliationDr Karl Thomae Gmbh, Biberach, West Germany.lld:pubmed
pubmed-article:2604748pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2604748pubmed:publicationTypeComparative Studylld:pubmed